Jack Anders sold $401k of RVMD
Chief Financial Officer at Revolution Medicines, Inc.. 10,000 shares at an average of $40.10, traded Sep 2, 2025, filed Sep 4, 2025.
Score components
- +22RoleCFO
- +16Trade size$401k at market
- 0Share of holdings soldSold 8.5% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-25-000326, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 2, 2025 | MOption exercise Common Stock10b5-1 | +2,814 | $2.68 | $7,542 | 116,128 | Sep 4, 2025 |
| Sep 2, 2025 | MOption exercise Common Stock10b5-1 | +1,948 | $4.73 | $9,214 | 118,076 | Sep 4, 2025 |
| Sep 2, 2025 | SOpen-market sale Common Stock10b5-1 | -4,762 | $40.02 | $191k | 113,314 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +3,189 | $4.73 | $15k | 116,503 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Common Stock10b5-1 | +2,049 | $17.00 | $35k | 118,552 | Sep 4, 2025 |
| Sep 3, 2025 | SOpen-market sale Common Stock10b5-1 | -5,238 | $40.17 | $210k | 113,314 | Sep 4, 2025 |
| Sep 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,814 | $0.00 | $0 | 0 | Sep 4, 2025 |
| Sep 2, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,948 | $0.00 | $0 | 3,189 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,189 | $0.00 | $0 | 0 | Sep 4, 2025 |
| Sep 3, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,049 | $0.00 | $0 | 15,418 | Sep 4, 2025 |
Related signals
Other insiders at Revolution Medicines, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | Revolution Medicines, Inc. | Alan B. Sandler Chief Development Officer | $1.3M 6,309 shares | -11% | |
| 21Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $159k 765 shares | -1% | |
| 16Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $743k 3,708 shares | -9% | |
| 40Moderate | Revolution Medicines, Inc. | Elizabeth M Anderson director | $2.0M 10,143 shares | -70% | |
| 25Weak | Revolution Medicines, Inc. | Anthony Mancini See Remarks | $347k 1,764 shares | -4% | |
| 39Weak | Revolution Medicines, Inc. | Jack Anders Chief Financial Officer | $808k 4,053 shares | -3% | |
| 30Weak | Revolution Medicines, Inc. | Jeff Cislini SVP & General Counsel | $671k 3,366 shares | -6% | |
| 35Weak | Revolution Medicines, Inc. | Mark A Goldsmith See Remarks | $2.8M 13,988 shares | -5% | |
| 40Moderate | Revolution Medicines, Inc. | Margaret A Horn Chief Operating Officer | $990k 4,967 shares | -3% | |
| 35Weak | Revolution Medicines, Inc. | Stephen Michael Kelsey See Remarks | $1.1M 5,569 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.